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Summary
Most countries provide national screening programs for early detection and prevention of colorectal cancer (CRC). As 
a result, the incidence and mortality are becoming slightly divergent. Croatian colorectal cancer screening program has 
 begun in 2007 with overall response rate about 20%. This response rate, may be explained by complexity of fecal occult 
blood test (FOBT) and availability of colonoscopy for positive results.
Recently, European countries started replacing FOBT test in national screening programs with fecal immunochemical 
test (FIT), which is based on immunochemical method performed by automatic analyzer using the specially designed high-
ly specific antibodies that could detect human hemoglobin exclusively. The main advantages of FIT are higher sensitivity 
for detection of cancer and higher proportion of true negative.
The aim of the national screening program is to detect the disease as early as possible when CRC is curable. Providing 
information on colorectal cancer to general public, along with current national plan and through the application of current 
guidelines it is possible to increase response rate, early detection, improve quality of life and increase overall survival.
In this paper we discuss a possibility of replacing FOBT with FIT attributing to these goals.
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USPOREDBA FIT-a I FOBT-a U PROBIRU ZA KOLOREKTALNI KARCINOM
Sa`etak
Ve}ina zemalja ima Nacionalni program za rano otkrivanje i prevenciju raka debelog i zavr{nog crijeva (KRK). Kao 
rezultat, incidencija i mortalitet postaju divergentni. Hrvatski program ranog otkrivanja raka debelog crijeva zapo~eo je 
2007 s odazivom od oko 20%. Odaziv se mo`e objasniti slo`eno{}u izvo|enja testa na okultno krvarenje i dostupno{}u 
 kolonoskopije nakon pozitivnog testa.
Odnedavno, Europske zemlje su po~ela zamijenjivati standardni test na okultno krvarenje imunohistokemijskim 
 testom koji se temelji na protutijelima visokospecifi~nim na hemoglobin. Glavne prednosti imunokemijskog testa su ve}a 
osjetljivost u otkrivanju raka i ve}i stupanj detekcije zaista negativnih uzoraka.
Cilj nacionalnog programa je rano otkrivanje bolesti, kada je kolorektalni karcinom izlje~iv. Informiranost o kolorek-
talnom karcinomu, postoje}i nacionalni program probira i njegova implementacija, te pra}enje trenutnih smjernica omogu}ili 
bi pove}ani odgovor na program probira, raniju detekciju, pobolj{ali kvalitetu `ivota i ukupno pre`ivljenje.
U ovom radu razmatrano potencijalni doprinos zamjene, testa na okultno krvarenje s imunohistokemijskim testom u 
program probira.
KLJU^NE RIJE^I: test na okultno krvarenje (Hemokult), imunokemijski test (FIT), kolorektalni karcinom, probir
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SCREENING PROGRAMS
Forming the framework and the network for 
systematic early colorectal cancer (CRC) detection 
in Croatia officially began in 2007, when the Pro-
posal of the National Program for Early Colorectal 
Cancer had been accepted (1).
The accepted program was in line with the 
main guidelines of the former National Health 
Development Strategy 2006-11, as well as interna-
tional strategic health documents: Resolution of 
prevention and control of the cancer by WHO 
from the2005, and the European Union Council 
Recommendations from 2003(878/EZ) (2,3,4). The 
main goal of the program was implementing pre-
ventive procedures for early detection of malig-
nant colorectal tumors at stage of limited prema-
lignant lesions and early cancer, which is a basic 
requirement for increased survival rate.
The programs’ holders were Croatian Minis-
try of Health and the Croatian Health Insurance 
Fund. Targeted groups were men and women 
over 50 years who were invited to participate by 
performing the fecal occult blood testing. Actions 
important for achieving the greatest possible re-
sponse to the screening (preparing and distribu-
tion of brochures, media campaign, educations of 
the health staff and participants of the screening...) 
were defined. Designated goals of the program 
were mortality reduction for 15% in five years af-
ter initializing the program with response rate up 
to 60% (1).
Subsequent national strategic document – 
Plan for Development of the Public Health 2011-
2015 in Croatia emphasizes the priority of in-
creased response rate of the target population in 
comparison to the first round of screening (5). 
Without going in to specific causes, objective prob-
lem of the program was relatively low response 
rate (from 1056694 invited persons only 209763 of 
them returned samples) (6).
Systematic colorectal cancer prevention, im-
plemented as annual or biannual screening pro-
gram contributes significantly to statistically sig-
nificant CRC mortality reduction of 15-40%, which 
confirms the efficacy of the secondary colorectal 
cancer prevention by detection in the early stage 
(7, 8) since transition from localized CRC curable 
stage (stage I) to metastatic disease (stage IV) is a 
slow process that can last up to ten years.
EPIDEMIOLOGICAL DATA, 
RISK FACTORS, AND METHODS 
OF PRIMARY AND SECONDARY 
PREVENTION
The most comprehensive global data on the 
assessment about tumors incidence, mortality and 
prevalence are provided by the International 
Agency for Research in Cancer (IARC) part of the 
World Health Organization through the GLOBO-
CAN Project. These are obtained from a total of 
184 national registries worldwide (9, 10).When 
that data is converted to absolute numbers, the to-
tal number of new cases in Europe has almost 
reached the number of 450000, and almost 215 000 
have died (11).
Data concerning the incidence of CRC in Cro-
atia show 3209 new cases in 2012: 1863 men and 
1406 women. In 2012, 1149 men and 861 women 
died from colorectal cancer. Reviewed chronologi-
cally, numbers of CRC cases in Croatia also indi-
cate a trend of continuous increase in the last two 
decades: 1990 (1648 new cases of CRC); 2000 – 
(2700 new cases of CRC); 2005 – (2846 new cases of 
CRC); 2010 – (3067 new cases of CRC) (12).
The same situation is globally present and is 
considered as particularly alarming. Despite the 
progress in diagnostic, surgical and therapeutic 
procedures, the incidence and mortality of CRC 
has an increasing trend (approximately 3% per 
year). Additionally, the risk increases significantly 
with age, especially after 40 years, and almost 
doubles with each subsequent decade of life. Ev-
ery person older than 50 years carries 5% (1/20) 
risk of suffering and 2.5% (1/40) risk of dying be-
fore 74 years from CRC (12). Risk factors that con-
tribute to the development of CRC can be classi-
fied in to several basic categories: genetic (family 
history is present in one quarter of the patients); 
environmental (diet, physical activity, obesity, di-
abetes, smoking…), other pathophysiological con-
ditions (previous colorectal cancer, adenomas, 
polyps, ulcerative colitis, Crohn’s disease...). 
Symptoms suggestive of CRC are occult or overt 
bleeding in the stool, a change in the cycle, shape 
and consistency of stools, abdominal pain and 
anemia (13, 14, 15).
Despite the fact that in 80% CRC patients, 
disease is detected in operable stage, 40-45% of 
them relapse in next five years, often with fatal 
outcome. It is therefore understandable that the 
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priority is to diagnose the disease in an earlier 
stage (stages I and II), before dissemination (stages 
III and IV). Studies have shown that the detection 
of CRC in the first stage provides a high probabil-
ity of 5-year survival (95%) (16, 17).
Considering the above, as well as the signifi-
cant contribution of genetic factors, The American 
Cancer Society categorized CRC screening algo-
rithm and chose the optimal approach to preven-
tion. It is tailored for: a) the general population 
(average risk); b) population with moderately in-
creased risk; and finally c) high-risk population. 
In fact, a first relative who has been diagnosed 
with CRC increases the likelihood of developing 
CRC by 1.5; and two affected first relatives in-
crease probability by 3-4 times compared to the 
general population (18).
Generally, CRC primary prevention methods 
are not systematized and organized. They are 
mostly focused to risk factors identification and 
correction, as well as general recommendations 
for proper diet (limited intake of refined sugar 
and red meat, fulfilling the need for carbohydrates 
mostly from fruit and vegetables, fulfilling the 
need for protein mostly from white meat and fish, 
reducing intake of saturated fatty acids…), sup-
plement intake of essential nutrients (vitamin D, 
folic acid, selenium, calcium...), as well as recom-
mendations for healthy living (maintaining ideal 
body weight, physical activity, reduce alcohol 
consumption and smoking). 
The essence of successfully implemented 
CRC secondary prevention is diagnosis the bigger 
proportion of patients in early stages of the dis-
ease-increasing the number of patients treated 
with curative intent and subsequently increase the 
survival rate (19, 20).
gFOBT vs. FIT
By using guiaiac fecal occult blood test 
(gFOBT) testing presence of blood in the stool is 
detected based on pseudoperoxidative perfor-
mance of haemoglobin, which in the presence of 
hydrogen peroxide converts guiaiacolalphaac-
idor2,5-di-(4-hydroxy-3-methoxyphenyl) -3,4-di-
methylphuran into blue colored quinone. Test 
qualitatively detects the presence of hemoglobin, 
but its objective limitation is the fact is that reagent 
does not react and detects hemoglobin of human 
origin only, but also reacts with hemoglobin from 
food (like red meat), or peroxidase (usually from 
vegetables). Because of that it is necessary, before 
preforming the test, to inform the participants on 
proper diet (excluding those ingredients in food 
which significantly positively interfere with the 
method). Unlike qualitative gFOBT, fecal immu-
nochemical test (FIT) is a quantitative immuno-
chemical method which is performed by automat-
ic analyzer using the specially designed highly 
specific antibodies that could detect human hemo-
globin exclusively. Additional gFOBT limiting 
factor compared with FIT is the possibility of 
falsely positive results because of the drugs inter-
ference (NSAIDs, aspirin, vitamin C) (21, 22, 23).
The relatively low response rate to CRC 
screening programs might be due to uneasiness 
when performing the test. gFOBIT is performed 
on three consecutive days and requests direct stool 
manipulation by participants (smearing stool on 
the card). Performing FIT is easier for subjects, the 
Table1.
COMPARISON OF gFOBT AND FIT.
gFOBT FIT
Qualitative test Quantitative test
React sand gives false positive 
result with non-human 
hemoglobin (food)
Does not react and gives false 
positive result with non-human 
hemoglobin (food)
React sand gives false positive 
result with peroxidase from 
vegetables
Does not react and gives false 
positive result with peroxidase 
from vegetables
Require several days of food 
restriction prior to conducting 
the test
Does not require several days 
of food restriction prior to 
conducting the test
Positive interference NSAIDs, 
aspirin and vitamin C
Without drug interference 
Require consecutive stool 
collection in three consecutive 
days
Does not require consecutive 
stool collection in three 
consecutive days
Screened persons should 
directly manipulate with the 
feces during the performance 
test
Screened persons should not 
directly manipulate with the 
feces during the performance 
test, they sent the sample for 
analysis
Method is not automated and 
standardized
Completely automated and 
standardized method
Sensitivity:
adenoma ≤ 5 mm: 1-5%
adenoma 6-9 mm: 5-13,7%
adenoma ≥ 10 mm: 8,9-27,5 %
CRC: 25-50%
Sensitivity:
adenoma ≤ 5 mm: 2-7,5%
adenoma 6-9 mm: 7,5-24%
adenoma ≥ 10 mm: 16-48 %
CRC: 50-87%
The negative predictive value 
for advanced adenoma sand 
CRC:84 %
The negative predictive value 
for advanced adenoma sand 
CRC:96 %
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sample is taken once or twice, without additional 
direct manipulation with stool. After samples are 
collected, participants bring the samples to the 
collection site (for example primary medical care 
ambulance) from where are the samples trans-
ported to the central laboratory where quantita-
tive and specific immunochemical measurement 
on fresh samples is performed which remains the 
same as for FOBT. 
EXPERIENCE OF THE OTHERS COUNTRIES
The systematic implementation of national 
screening program for CRC using FIT started in 
Italy, in 2011. From 3.5 million invited persons 
48% of them responded. At the initial screening, 
5.5% were positive. 1000 cohort revealed a 2.4 in-
vasive tumors and 10.3 advanced adenomas (>10 
mmin diameter and / or high grade dysplasia) 
(24). The similar experiences was in Spain, where 
pilot program of CRC screening with FIT began in 
2009., and from 197.839 invited (Barcelona area) 
has achieved the response rate of 43.5%, and the 
proportion of 6.2% positive. They have detected 
1639 high risk adenomas and 245 invasive CRCs. 
The authors stated that CRC detection of using 
FIT is comparable to colonoscopy (25). An impor-
tant argument for FIT implementation into the na-
tional screening programs in many countries (Ita-
ly, France, Netherlands, Spain, Slovenia, Japan, 
Australia, New Zealand, United Kingdom) cer-
tainly was almost double diagnostic sensitivity of 
FIT in the detection of advanced (greater diame-
ter) adenomas compared with gFOBT (48 vs. 27%, 
5%), and higher sensitivity in the detection of can-
cer (25-50% with gFOBT vs. 50-87% FIT) (24, 25, 
26, 27, 28).
Additional deficiency of gFOBIT in compari-
son to the FIT is a relatively high proportion of 
false positive results, which complicates the whole 
screening program by requiring a greater number 
of unnecessary colonoscopies, with all the compli-
cations that those carry (29). In Ireland it is esti-
mated that the change from a gFOBIT to FITon 
200 000 participants could detect 500 CRC more 
(309 by gFOBIT vs. 853 by FIT) (30). In The Neth-
erlands study on 20623 participants has detected 
over twice as many adenomas and CRC using FIT 
(5.5%) compared to gFOBIT (2.4%). One of the rec-
ommended items of the Guidelines for Colorectal 
Cancer Screening of The American College of Gas-
troenterology is: FIT replaces older guaiac-based 
fecal occult blood testing. FIT is the preferred can-
cer detection test (18).
Considering high negative predictive poten-
tial of the FIT (what is a direct consequence of the 
higher proportion of truly negative, and lower 
proportion of falsely negative results), it became a 
test that The Europa Colon association preferred 
to the gFOBIT. Europa Colon gives recommenda-
tions which are harmonized with the statement of 
the European Cancer Society on its website. Un-
der the auspices of the World Endoscopy Organi-
zation, Colorectal Cancer Screening Committee is 
working and meets every year, in 2013 for the 
third time in a row, and has confirmed that the FIT 
program is ideal for CRC screening (31, 32).
STREESSING THE OBJECTIVES 
OF THE SCREENING PROGRAM
Achieving a successful screening program 
for colorectal cancer is considered a key to achieve 
higher survival rates for the colorectal cancer pa-
tients. For its success it is necessary to review all 
involved and their perspectives with possible im-
provement on each phase. From a laboratory and 
biochemical point of view FIT has better perfor-
mance than gFOBT. It has immediate financial im-
plications which might be neutralized when in-
corporating benefits into the calculus. However, 
every implementation into a large scale system 
needs time and adjustments and logistics. In the 
meantime, the main point of all screening pro-
grams is population awareness of incidence and 
symptoms of colorectal cancer as well as availabil-
ity of diagnostics and treatment that should be 
stressed and worked on continously.
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